New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export JNJ’s income statement to Excel — free account
Johnson & Johnson
JNJHealthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
270.19
3.09
+1.16%
Follow JNJ
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow of $6.4B covered $4.2B of dividends and buybacks. Cash fell by $3.5B. What is a cash flow statement?
- Free cash flow
- $6.4B 82.3% of operating cash flow
- Returned to shareholders
- $4.2B 66.0% of free cash flow
- Debt, net
- −$4.4B repaid
- Change in cash
- −$3.5B over the period
| Operating cash flow | 7.7 |
|---|---|
| Capital expenditures | −1.4 |
| Free cash flow | 6.4 |
| Acquisitions, net | −0.1 |
| Into investments, net | −0.6 |
| Dividends | −3.2 |
| Buybacks, net | −1.0 |
| Debt repaid, net | −4.4 |
| Other | −0.6 |
| Change in cash | −3.5 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $7.3B | $2.5B | $8.6B | $7.7B |
| Capex | −$1.5B | −$1.0B | −$1.3B | −$1.4B |
| Free cash flow | $5.8B | $1.5B | $7.4B | $6.4B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
210.00 | 5,534.00 | 5,235.00 | 5,116.00 |
+8 more quarters Free account |
Depreciation & Amortization |
2,117.00 | 1,959.00 | 2,004.00 | 2,011.00 | |
Non Cash Items (Other) |
126.00 | 108.00 | 509.00 | (3,419.00) | |
Accounts Receivable Change |
205.00 | (1,356.00) | (603.00) | 396.00 | |
Change in inventories |
(150.00) | (571.00) | (431.00) | (46.00) | |
Change in payables and accrued liability |
2,405.00 | 2,964.00 | (3,920.00) | 1,266.00 | |
Change in other assets and liabilities |
2,807.00 | (22.00) | (280.00) | 1,985.00 | |
Operating Cash Flow |
7,720.00 | 8,616.00 | 2,514.00 | 7,309.00 | |
Capital expenditures |
(1,366.00) | (1,258.00) | (1,020.00) | (1,525.00) | |
Net Aquisitions |
(89.00) | (263.00) | — | (3,082.00) | |
Long-Term Investments Change (Net) |
(611.00) | 4.00 | 65.00 | (24.00) | |
Other investing activities |
(643.00) | 407.00 | (85.00) | 146.00 | |
Investing cash flow |
(2,709.00) | (1,110.00) | (1,040.00) | (4,485.00) | |
Repayment/Issuance of Debt (Net) |
(4,358.00) | (5,748.00) | 7,214.00 | 2,105.00 | |
Equity Repurchase (Common, Net) |
(966.00) | 138.00 | (2,856.00) | (337.00) | |
Dividends Paid (Total) |
(3,227.00) | (3,227.00) | (3,131.00) | (3,131.00) | |
Other financial activities |
18.00 | 60.00 | (697.00) | (6.00) | |
Financing cash flow |
(8,533.00) | (8,777.00) | 530.00 | (1,369.00) | |
Exchange Rate Adjustment |
10.00 | 5.00 | (25.00) | 23.00 | |
Change in Cash |
(3,512.00) | (1,266.00) | 1,979.00 | 1,478.00 | |
Beginning Cash |
0.00 | 0.00 | 19,709.00 | 0.00 | |
Ending Cash |
(3,512.00) | (1,266.00) | 21,688.00 | 1,478.00 | |
Stock Based Compensation |
357.00 | 458.00 | 300.00 | 309.00 | |
Dividends Paid (Common) |
(3,227.00) | (3,227.00) | (3,131.00) | (3,131.00) | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
5,267.00 | 1,015.00 | (5,234.00) | 3,601.00 | |
Investments Change (Net) |
(611.00) | 4.00 | 65.00 | (24.00) | |
Issuance/Purchase of Shares |
(966.00) | 138.00 | (2,856.00) | (337.00) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026